FeesSafety
Pluang+

Edgewise Therapeutics starts Phase 2 trial of EDG-15400 for heart failure with preserved ejection fraction (HFpEF).

Market News
08 Oct 2026, 15:00 WIB
PRNewsWire
View Source
Bullish
Edgewise Therapeutics starts Phase 2 trial of EDG-15400 for heart failure with preserved ejection fraction (HFpEF).

Edgewise Therapeutics has begun dosing the first patient in its Phase 2 EQUINOX-HFpEF trial, testing EDG-15400, an oral drug aimed at improving cardiac relaxation in adults with symptomatic heart failure with preserved ejection fraction (HFpEF). This trial will evaluate the drug's safety, tolerability, and effects in about 90 patients over 12 weeks. HFpEF is a challenging heart failure type with limited treatment options, and EDG-15400 targets the underlying diastolic dysfunction. Results and trial design will be presented at the HFSA 2026 meeting in October.

Edgewise Therapeutics' Phase 2 EQUINOX-HFpEF trial initiation is noted here alongside Pluang's health sector market snapshot. As of Oct 08, 2026 18:11 WIB, among 100 priced health-sector US stocks on Pluang, 25 rose and 68 fell. Notable movers include TXG at USD 73.85 with 74% sell order activity, SANA at USD 2.80 with 73% buy order activity, and RXRX at USD 4.15 with 95% sell order activity.

More News

DeGen Medical moves to dismiss Carlsmed's patent suit over spinal implant methods.

DeGen Medical moves to dismiss Carlsmed's patent suit over spinal implant methods.

DeGen Medical has filed a motion to dismiss key parts of a patent infringement lawsuit from Carlsmed, which claims DeGen's patient-specific spinal implants infringe on eight patents. DeGen argues that the contested patents cover abstract, computer-im...

Market News
Neutral
2 hours ago
SoFi projects 50% earnings growth in 2027 and no need for new capital raises.

SoFi projects 50% earnings growth in 2027 and no need for new capital raises.

SoFi announced it expects about 50% growth in earnings for 2027, signaling strong financial performance ahead. The company also stated it will not need to raise new capital, indicating confidence in its current funding and business model. This outloo...

Company Fundamentals
Bullish
4 hours ago
Hyperliquid (HYPE) price drops 2.01% in one hour despite 24-hour gains

Hyperliquid (HYPE) price drops 2.01% in one hour despite 24-hour gains

Hyperliquid (HYPE) experienced a 2.01% price decline within one hour, falling from $68.12 to $66.75 based on Binance's HYPE/USDT trading pair. Despite this short-term drop, HYPE's 24-hour price change remained positive at +5.13%. During the same hour...

Market News
Bearish
5 hours ago
Solana Foundation hires key researchers behind Alpenglow upgrade to advance network protocol work

Solana Foundation hires key researchers behind Alpenglow upgrade to advance network protocol work

Roger Wattenhofer and Quentin Kniep, researchers involved in Solana's Alpenglow consensus upgrade, are joining the Solana Foundation to continue developing the network's protocol. They previously worked at Anza, a software developer for Solana, where...

Protocol Fundamentals
Bullish
5 hours ago
Aave enables Bitcoin as collateral to boost DeFi liquidity and stablecoin borrowing amid market downturn.

Aave enables Bitcoin as collateral to boost DeFi liquidity and stablecoin borrowing amid market downturn.

Aave has approved using Bitcoin as collateral for borrowing stablecoins, aiming to unlock new liquidity sources in DeFi amid a liquidity crunch. This move allows BTC holders to borrow against multiple stablecoins, including USDT and USDC, potentially...

Protocol Fundamentals
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App